Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

Juanjuan Zhao; Quan Ren; Xinyuan Liu; Xiangqian Guo; Yongping Song

doi:10.1186/s13045-023-01489-3

Journal of Hematology & Oncology (Aug 2023)

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

Juanjuan Zhao,
Quan Ren,
Xinyuan Liu,
Xiangqian Guo,
Yongping Song

Affiliations

Juanjuan Zhao: Department of Hematology, The First Affiliated Hospital of Zhengzhou University
Quan Ren: Department of Hematology, The First Affiliated Hospital of Zhengzhou University
Xinyuan Liu: Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University
Xiangqian Guo: Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University
Yongping Song: Department of Hematology, The First Affiliated Hospital of Zhengzhou University

DOI: https://doi.org/10.1186/s13045-023-01489-3
Journal volume & issue: Vol. 16, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment of MM from the ASCO 2023 Annual Meeting.

Published in Journal of Hematology & Oncology

ISSN: 1756-8722 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jhoonline.biomedcentral.com/

About the journal

Abstract

Keywords